Aardvark Therapeutics (AARD) Net Cash Flow (2024 - 2026)
Aardvark Therapeutics (AARD) reported Net Cash Flow of $15.4 million for Q1 2026, up 143.79% on a YoY basis from $6.3 million in Q1 2025, and up 98.11% sequentially from $7.8 million in Q4 2025.
Aardvark Therapeutics (AARD) Net Cash Flow (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Net Cash Flow data on file, last reported at $15.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 143.79% year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $35.9 million (up 89.47% YoY), and the FY2025 full-year result was -$14.6 million, down 128.11% from the prior year.
- Net Cash Flow advanced to $15.4 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $78.6 million in Q2 2024 to a low of -$35.1 million in Q1 2025.
- A 3-year average of $5.9 million and a median of -$506000.0 in 2025 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 441.04% in 2025, while the deepest fall reached 1500.77% in 2025.
- Tracing AARD's Net Cash Flow over 3 years: stood at -$20.6 million in 2024, then jumped by 137.63% to $7.8 million in 2025, then jumped by 98.11% to $15.4 million in 2026.
- Business Quant data shows AARD's Net Cash Flow at $15.4 million in Q1 2026, $7.8 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | 15.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.39 Mn |
| Mar 31, 2026 | 15.39 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Sep 30, 2025 | 13.29 Mn |
| Sep 30, 2025 | 13.29 Mn |
| Jun 30, 2025 | -506,000.00 |
| Jun 30, 2025 | -506,000.00 |
| Mar 31, 2025 | -35.14 Mn |
| Mar 31, 2025 | -35.14 Mn |
| Dec 31, 2024 | -20.64 Mn |
| Dec 31, 2024 | -20.64 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Jun 30, 2024 | 78.63 Mn |
| Jun 30, 2024 | 78.63 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |